Clozapine Plasma Level Monitoring: Current Status

Overview

Journal Psychiatr Q

Specialty Psychiatry

Date 1996 Jan 1

PMID 8938830

Citations 7

Authors

T B Cooper

Affiliations

Soon will be listed here.

Abstract

Plasma level monitoring of clozapine and metabolites may prove beneficial in treating patients who show unusual drug metabolic activity. A threshold plasma level for patients who will respond to this medication is suggested. The interaction of gender, age, smoking, other medication and side effects with plasma clozapine and metabolites are discussed. Plasma level monitoring of clozapine and/or metabolites is recommended in patients who do not respond at usual therapeutic dose, who show untoward side effects at low dose or who are treated with other medications. Finally monitoring of patients who require more than 600 mg/day should be implemented because there is evidence that the incidence of seizures increases significantly above this dosage level. There is some evidence that high plasma clozapine levels are associated with seizures.

Citing Articles

Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia.

Lee J, Kim M, Jeong H, Shin K Transl Clin Pharmacol. 2021; 29(1):33-44.

PMID: 33854999 PMC: 8020364. DOI: 10.12793/tcp.2021.29.e3.

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Howes O, McCutcheon R, Agid O, de Bartolomeis A, van Beveren N, Birnbaum M Am J Psychiatry. 2016; 174(3):216-229.

PMID: 27919182 PMC: 6231547. DOI: 10.1176/appi.ajp.2016.16050503.

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Lally J, Gaughran F, Timms P, Curran S Pharmgenomics Pers Med. 2016; 9:117-129.

PMID: 27853387 PMC: 5106233. DOI: 10.2147/PGPM.S115741.

Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?.

Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V Psychopharmacology (Berl). 2012; 225(3):505-18.

PMID: 23179967 DOI: 10.1007/s00213-012-2922-7.

Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Mauri M, Volonteri L, Colasanti A, Fiorentini A, De Gaspari I, Bareggi S Clin Pharmacokinet. 2007; 46(5):359-88.

PMID: 17465637 DOI: 10.2165/00003088-200746050-00001.

References

Fadiran E, Leslie J, Fossler M, Young D . Determination of clozapine and its major metabolites in human serum and rat plasma by liquid chromatography using solid-phase extraction and ultraviolet detection. J Pharm Biomed Anal. 1995; 13(2):185-90. DOI: 10.1016/0731-7085(93)e0020-n. View

Haring C, Fleischhacker W, Schett P, Humpel C, Barnas C, Saria A . Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry. 1990; 147(11):1471-5. DOI: 10.1176/ajp.147.11.1471. View

Kronig M, Munne R, Szymanski S, Safferman A, Pollack S, Cooper T . Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 1995; 152(2):179-82. DOI: 10.1176/ajp.152.2.179. View

Brosen K, Skjelbo E, Rasmussen B, Poulsen H, Loft S . Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993; 45(6):1211-4. DOI: 10.1016/0006-2952(93)90272-x. View

Choc M, Hsuan F, HONIGFELD G, Robinson W, Ereshefsky L, Crismon M . Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res. 1990; 7(4):347-51. DOI: 10.1023/a:1015859103824. View

Nordstrom A, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G . D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry. 1995; 152(10):1444-9. DOI: 10.1176/ajp.152.10.1444. View

Markowitz J, Patrick K . Thermal degradation of clozapine-N-oxide to clozapine during gas chromatographic analysis. J Chromatogr B Biomed Appl. 1995; 668(1):171-4. DOI: 10.1016/0378-4347(95)00060-v. View

McCarthy P, Hughes S, Paton C . Measurement of clozapine and norclozapine in plasma/serum by high performance liquid chromatography with ultraviolet detection. Biomed Chromatogr. 1995; 9(1):36-41. DOI: 10.1002/bmc.1130090108. View

Centorrino F, Baldessarini R, Flood J, Kando J, Frankenburg F . Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites. Am J Psychiatry. 1995; 152(4):610-2. DOI: 10.1176/ajp.152.4.610. View

10.

Devinsky O, HONIGFELD G, PATIN J . Clozapine-related seizures. Neurology. 1991; 41(3):369-71. DOI: 10.1212/wnl.41.3.369. View

11.

Miller D . Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry. 1991; 52(1):23-5. View

12.

Jennison T, Brown P, Crossett J, Kushnir M, Urry F . A rapid gas chromatographic method quantitating clozapine in human plasma or serum for the purpose of therapeutic monitoring. J Anal Toxicol. 1995; 19(7):537-41. DOI: 10.1093/jat/19.7.537. View

13.

McEvoy J, Hogarty G, Steingard S . Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991; 48(8):739-45. DOI: 10.1001/archpsyc.1991.01810320063009. View

14.

Pirmohamed M, Williams D, Madden S, Templeton E, Park B . Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995; 272(3):984-90. View

15.

Heipertz R, Pilz H, Beckers W . Serum concentrations of clozapine determined by nitrogen selective gas chromatography. Arch Toxicol. 1977; 37(4):313-8. DOI: 10.1007/BF00330823. View

16.

McEvoy J, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J . Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995; 37(8):550-2. DOI: 10.1016/0006-3223(94)00365-A. View

17.

Farde L, Nordstrom A, Wiesel F, Pauli S, Halldin C, Sedvall G . Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49(7):538-44. DOI: 10.1001/archpsyc.1992.01820070032005. View

18.

George T, Sernyak M, Ziedonis D, Woods S . Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry. 1995; 56(8):344-6. View

19.

Fischer V, Vogels B, Maurer G, Tynes R . The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther. 1992; 260(3):1355-60. View

20.

Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H . EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology (Berl). 1994; 114(1):97-100. DOI: 10.1007/BF02245449. View